PMC12474311::PEP000001
Vaccines · 2025
Sequence evidence
SLLMWITQC
SLLMWITQC
Experimental observations
TCR-T cells showed the greatest functional avidity for T2 cells, with an EC50 of 0.004 μM (Section 3.3, Figure 3a).
The functional avidity of COS-7-A*02:01 was lower than that of the T2 cells, with an EC50 of 0.036 μM (Section 3.3, Figure 3b).
The EC50 values of functional avidity for A*02:03 ... were 0.995 μM (Section 3.3, Figure 3c).
The EC50 values of functional avidity for A*02:05 ... were 0.188 μM (Section 3.3, Figure 3d).
The EC50 values of functional avidity for A*02:06 ... were 0.351 μM (Section 3.3, Figure 3e).
The EC50 values of functional avidity for A*02:10 were 0.239 μM (Section 3.3, Figure 3f).
TCR-T cells not only recognized the NY-ESO-1 peptide presented by HLA-A*02:01 but also HLA-A*02:03, HLA-A*02:05, HLA-A*02:06, and HLA-A*02:10 (Section 3.2, Figure 2a).
TCR-T cells not only recognized the NY-ESO-1 peptide presented by HLA-A*02:01 but also HLA-A*02:03, HLA-A*02:05, HLA-A*02:06, and HLA-A*02:10 (Section 3.2, Figure 2a).
TCR-T cells not only recognized the NY-ESO-1 peptide presented by HLA-A*02:01 but also HLA-A*02:03, HLA-A*02:05, HLA-A*02:06, and HLA-A*02:10 (Section 3.2, Figure 2a).
TCR-T cells not only recognized the NY-ESO-1 peptide presented by HLA-A*02:01 but also HLA-A*02:03, HLA-A*02:05, HLA-A*02:06, and HLA-A*02:10 (Section 3.2, Figure 2a).
TCR-T cells not only recognized the NY-ESO-1 peptide presented by HLA-A*02:01 but also HLA-A*02:03, HLA-A*02:05, HLA-A*02:06, and HLA-A*02:10 (Section 3.2, Figure 2a).
Limited activity was observed for the NY-ESO-1 peptide with HLA-A*02:09 and HLA-A*02:11 alleles (Section 3.2, Figure 2a).
Limited activity was observed for the NY-ESO-1 peptide with HLA-A*02:09 and HLA-A*02:11 alleles (Section 3.2, Figure 2a).
TCR-T cells were not active for the peptides presented by HLA-A*02:07 and HLA-A*02:48 (Section 3.2, Figure 2a).
TCR-T cells were not active for the peptides presented by HLA-A*02:07 and HLA-A*02:48 (Section 3.2, Figure 2a).
Endogenous NY-ESO-1 peptide presented by HLA-A*02:01, HLA-A*02:03, HLA-A*02:05, HLA-A*02:06, and HLA-A*02:10 significantly induced TCR-T cells to secrete higher levels of IFN-γ than control T cells (Section 3.2, Figure 2b).
Endogenous NY-ESO-1 peptide presented by HLA-A*02:01, HLA-A*02:03, HLA-A*02:05, HLA-A*02:06, and HLA-A*02:10 significantly induced TCR-T cells to secrete higher levels of IFN-γ than control T cells (Section 3.2, Figure 2b).
Endogenous NY-ESO-1 peptide presented by HLA-A*02:01, HLA-A*02:03, HLA-A*02:05, HLA-A*02:06, and HLA-A*02:10 significantly induced TCR-T cells to secrete higher levels of IFN-γ than control T cells (Section 3.2, Figure 2b).
Endogenous NY-ESO-1 peptide presented by HLA-A*02:01, HLA-A*02:03, HLA-A*02:05, HLA-A*02:06, and HLA-A*02:10 significantly induced TCR-T cells to secrete higher levels of IFN-γ than control T cells (Section 3.2, Figure 2b).
Endogenous NY-ESO-1 peptide presented by HLA-A*02:01, HLA-A*02:03, HLA-A*02:05, HLA-A*02:06, and HLA-A*02:10 significantly induced TCR-T cells to secrete higher levels of IFN-γ than control T cells (Section 3.2, Figure 2b).
TCR-T cells also exhibited activity for different HLA-A2 alleles other than HLA-A*02:01 according to ELISA (Section 3.4, Figure 4a). The activities were most potent for HLA-A*02:01, HLA-A*02:10, HLA-A*02:03, and HLA-A*02:06 but not for HLA-A*02:05.
TCR-T cells also exhibited activity for different HLA-A2 alleles other than HLA-A*02:01 according to ELISA (Section 3.4, Figure 4a). The activities were most potent for HLA-A*02:01, HLA-A*02:10, HLA-A*02:03, and HLA-A*02:06 but not for HLA-A*02:05.
TCR-T cells also exhibited activity for different HLA-A2 alleles other than HLA-A*02:01 according to ELISA (Section 3.4, Figure 4a). The activities were most potent for HLA-A*02:01, HLA-A*02:10, HLA-A*02:03, and HLA-A*02:06 but not for HLA-A*02:05.
TCR-T cells also exhibited activity for different HLA-A2 alleles other than HLA-A*02:01 according to ELISA (Section 3.4, Figure 4a). The activities were most potent for HLA-A*02:01, HLA-A*02:10, HLA-A*02:03, and HLA-A*02:06 but not for HLA-A*02:05.
The activities were most potent for HLA-A*02:01, HLA-A*02:10, HLA-A*02:03, and HLA-A*02:06 but not for HLA-A*02:05 (Section 3.4, Figure 4a).
624 mel cells, which are naturally double-positive cells (HLA-A*02:01+, NY-ESO-1+), exhibited potent activity toward TCR-T cells (Section 3.4, Figure 4a).
As expected, no activity was detected for the 586 mel WT strain (Section 3.4, Figure 4a).
Similar to 586 mel-A2 cells, TCR-T cells exhibited activity for different HLA-A2 alleles other than HLA-A*02:01 in 5637-NY-A2 cells (Section 3.4, Supplementary Figure S4).
Similar to 586 mel-A2 cells, TCR-T cells exhibited activity for different HLA-A2 alleles other than HLA-A*02:01 in 5637-NY-A2 cells (Section 3.4, Supplementary Figure S4).
Similar to 586 mel-A2 cells, TCR-T cells exhibited activity for different HLA-A2 alleles other than HLA-A*02:01 in 5637-NY-A2 cells (Section 3.4, Supplementary Figure S4).
Similar to 586 mel-A2 cells, TCR-T cells exhibited activity for different HLA-A2 alleles other than HLA-A*02:01 in 5637-NY-A2 cells (Section 3.4, Supplementary Figure S4).
As expected, no activity was detected in the 586 mel-WT, 5637-WT, and 5637-NY strains (Section 3.4).
As expected, no activity was detected in the 586 mel-WT, 5637-WT, and 5637-NY strains (Section 3.4).
Local peptide labels such as P1, PEP1, or peptide 1 are grouped only within this paper and are not assumed to represent the same molecule across publications.
